查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1918449

基于人工智慧的胜肽类药物发现平台市场（按技术类型、治疗用途、胜肽和最终用户划分）—2026-2032年全球预测

AI-driven Peptide Drug Discovery Platform Market by Technology Type, Therapeutic Application, Peptide Class, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

人工智慧驱动的胜肽药物发现平台市场预计到 2025 年将达到 10.8 亿美元，到 2026 年将成长到 12.1 亿美元，到 2032 年将达到 24.4 亿美元，复合年增长率为 12.29%。

关键市场统计数据
基准年 2025 10.8亿美元
预计年份：2026年 12.1亿美元
预测年份 2032 24.4亿美元
复合年增长率 (%) 12.29%

策略实施：运算能力与胜肽化学的融合正在重塑药物发现的优先事项，并加速生物製药领域的转化决策。

人工智慧驱动的胜肽类药物发现平台的出现，标誌着计算创新与胜肽化学的融合，重塑了治疗药物研发的早期阶段。过去几年，演算法建模的进步、计算能力的提升以及生物数据集的日益丰富，加速了具有更高特异性、稳定性和可生产性的胜肽类候选药物的筛选。本文阐述了将以资料为中心的药物发现流程整合到企业研发体系中的策略价值，重点介绍了机器辅助设计如何缩短候选药物筛选时间，同时为后续研发环节提供更可靠的决策支援。

快速的演算法进步、丰富的生物数据和可扩展的计算基础设施如何改变胜肽类药物发现工作流程和实用化预期

胜肽类药物发现领域正经历着一场变革，这场变革由三个相互关联的因素所驱动：演算法的复杂性、数据的可用性和操作的扩充性。深度学习架构正在不断发展，以更高的精度模拟序列-结构-功能关係，而基于图的方法和循环模型则能够对胜肽的相互作用和结构动态进行细緻入微的表征。同时，高品质基因组学和蛋白​​质组学数据集的激增以及更丰富的检测结果的出现，正在增强模型的训练和检验，使得计算假设能够更可靠地转化为实验检验。

评估2025年美国关税对胜肽类药物研发供应链、计算策略和实验优先排序的多面向影响

2025年美国关税的累积影响将为胜肽类药物研发价值链上的企业带来复杂的挑战与策略转捩点。影响实验室试剂、专用胜肽合成耗材以及某些计算硬体组件的关税将增加实验流程和基础设施投资的落地成本，进而影响筹资策略和计划优先排序。为此，一些企业正在考虑将关键合成产能迁回国内，或加强与区域供应商的合作，以确保供应的连续性和价格的可预测性。然而，这些供应侧措施通常需要前期投资和营运重组。

从技术架构、治疗领域重点、最终用户需求、胜肽类药物模式和工作流程步骤等方面进行全面的观点，从而实现策略平台选择和优先排序。

细緻的細項分析揭示了技术选择、治疗领域、最终用户画像、胜肽和工作流程阶段如何相互作用，从而定义独特的价值池和能力需求。从技术角度来看，平台涵盖范围广泛，从基于云端的选项（包括混合云端、私有云端和公共云端部署）、深度学习方法（例如卷积类神经网路、图神经网路和循环神经网路）、传统机器学习范式（例如强化学习、监督学习和无监督学习），到利用传统高效能运算和专用伺服器的本地部署平台。每种技术路径在可扩展性、资料管治以及演算法对序列最佳化和结构预测等任务的适用性方面都存在权衡取舍。

美洲、欧洲、中东和非洲以及亚太地区的趋势正在影响胜肽类药物研发倡议的平台采用、监管策略和供应链在地化。

区域趋势将显着影响从事人工智慧驱动胜肽类药物研发机构的投资决策、监管应对措施和供应链设计。在美洲，强大的创新生态系统、完善的创业融资管道以及位置的生物技术和製药公司，促进了计算平台的快速应用以及产业界与学术实验室之间的紧密合作。许多地区的监管政策清晰明确，支付体系完善，鼓励开展能够展现明确临床价值和可重复性的转化研究项目，而国内的生产能力则为早期候选药物的临床供应提供了保障。

结合胜肽化学专业知识和先进人工智慧技术以加速转化研发流程的公司之间，存在着一些关键的竞争和合作趋势。

主要企业层面的洞察揭示了通用人工智慧应用于胜肽类药物发现的领先企业所共有的策略模式。成功的公司通常会将胜肽化学专业知识与先进的运算能力结合，从而建立反馈迴路，加速模型最佳化和实验检验。他们投资跨职能团队，连接资料科学、结构生物学、药物化学和转化科学，以确保In Silico预测能够迅速透过经验数据得到验证，并不断迭代改进。

产业领导者应立即采取高影响力行动，协调平台选择、管治和伙伴关係，以加速、降低风险地开发胜肽类药物。

产业领导者应采取一套重点突出、切实可行的策略，将分析优势转化为持续的治疗和商业性成果。首先，应根据组织的风险状况选择合适的平台，评估云端扩展、混合部署或本地部署哪种方案最能满足资料隐私、监管限制和整体成本目标。其次，应优先组成整合团队，将计算模型开发人员、实验室研究人员和临床医生聚集在一起，以确保快速回馈和持续的模型检验。此外，还应建立迭代循环机制，并利用实验结果重新训练和改进演算法。

我们采用严谨的混合方法研究方法，结合一手访谈、技术审查和多源三角验证，以检验平台的说法和策略意义。

本研究整合了一手和二手研究方法，旨在提供基于实证的人工智慧赋能肽类药物发现现状分析。一手研究包括对製药和生物技术公司、受託研究机构（CRO）、学术实验室和技术提供者的领导层进行结构化访谈，并辅以对平台架构和检验研究的技术审查。二手研究则利用同行评审文献、监管指导文件、临床试验註册信息和公开信息，为研发路径和治疗重点提供背景资料。这些资讯经过三角验证，以确保结论的稳健性，并突显各相关人员之间的共识和分歧。

总之，我们总结了将人工智慧平台与营运严谨性和策略伙伴关係相结合的见解，以将计算胜肽药物发现转化为临床上有用的治疗方法。

总之，人工智慧驱动的胜肽类药物发现正从实验创新阶段过渡到企业加速治疗产品线研发的营运基础阶段。深度学习和基于图的建模技术的进步，结合可扩展的计算资源和丰富的生物数据集，使得In Silico模拟假设的生成和优先排序更加可靠。当这些能力得到确保可重复性和监管可追溯性的管治实践的支持，并融入跨职能团队时，才能发挥最大效用。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：基于人工智慧的胜肽类药物发现平台市场（按技术类型划分）

  • 基于云端的平台
    • 混合云端
    • 私有云端
    • 公共云端
  • 深度学习平台
    • 卷积类神经网路
    • 图神经网路
    • 循环神经网络
  • 机器学习平台
    • 强化学习
    • 监督式学习
    • 无监督学习
  • 本地部署平台
    • 传统高效能运算
    • 专用伺服器

9. 以人工智慧为基础的胜肽类药物发现平台市场（依治疗领域划分）

  • 心血管系统
    • 动脉粥状硬化
    • 心臟衰竭
  • 感染疾病
    • 细菌
    • 病毒性疾病
  • 代谢性疾病
    • 糖尿病
    • 肥胖
  • 神经系统疾病
    • 阿兹海默症
    • 帕金森氏症
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固态肿瘤

第十章：基于人工智慧的胜肽药物发现平台市场（按胜肽分类）

  • 环肽
    • 从头到尾
    • 侧链键类型
  • 线性胜肽
    • 长链胜肽
    • 短胜肽
  • 胜肽类似物
    • β胜肽
    • 胜肽类

第十一章：基于人工智慧的胜肽药物发现平台市场（按最终用户划分）

  • 学术和政府研究机构
    • 私人研究机构
    • 公共研究机构
  • 合约研究机构
    • 大型CRO机构
    • 小规模CRO组织
  • 製药和生物技术公司
    • 生技公司
    • 製药公司

第十二章：基于人工智慧的胜肽类药物发现平台市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：基于人工智慧的胜肽类药物发现平台市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国基于人工智慧的胜肽类药物发现平台市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国基于人工智慧的胜肽类药物发现平台市场

第十六章：中国基于人工智慧的胜肽类药物发现平台市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Atombeat, Inc.
  • Aurigene Discovery Technologies Limited
  • Cradle, Inc.
  • Creative Peptides, Inc.
  • Deep Genomics Inc.
  • DenovAI Biotech, Inc.
  • Fujitsu Limited
  • Generate Biomedicines, Inc.
  • Gubra ApS
  • Iktos SA
  • Insilico Medicine, Inc.
  • Koliber Biosciences, Inc.
  • Numerion Labs, Inc.
  • Nuritas Limited
  • Pepticom, Inc.
  • Peptilogics, Inc.
  • Relay Therapeutics, Inc.
  • Space Peptides, Inc.
Product Code: MRR-AE420CB1555D

The AI-driven Peptide Drug Discovery Platform Market was valued at USD 1.08 billion in 2025 and is projected to grow to USD 1.21 billion in 2026, with a CAGR of 12.29%, reaching USD 2.44 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.08 billion
Estimated Year [2026] USD 1.21 billion
Forecast Year [2032] USD 2.44 billion
CAGR (%) 12.29%

A strategic introduction to how combined computational power and peptide chemistry are reshaping discovery priorities and accelerating translational decision-making in biopharma

The emergence of AI-driven platforms for peptide drug discovery represents a convergence of computational innovation and peptide chemistry that is reshaping early-stage therapeutic development. Over the past several years, advances in algorithmic modeling, increased computational power, and richer biological datasets have accelerated the identification of peptide candidates with improved specificity, stability, and manufacturability. This introduction frames the strategic value of integrating data-centric discovery pipelines into organizational R&D, emphasizing how machine-assisted design reduces time to candidate selection while enabling higher-confidence decisions upstream in the pipeline.

Today's platform architectures vary from cloud-native solutions that scale training workloads to on-premise deployments designed to protect sensitive datasets, and this diversity reflects differing institutional risk tolerances and regulatory constraints. In parallel, the therapeutic landscape for peptides stretches across cardiovascular, infectious disease, metabolic, neurological, and oncology indications, each presenting unique target classes and validation needs. Academia and government laboratories continue to generate mechanistic insights, contract research organizations operationalize validation workflows, and pharmaceutical and biotechnology firms focus on translation and commercialization. By situating AI-driven peptide discovery within this ecosystem, stakeholders can better prioritize investments in platform capabilities, data governance, and cross-functional workflows that bridge computational predictions with empirical validation.

In short, integrating AI into peptide discovery is not a one-off efficiency gain but a structural shift that demands coordinated changes across technology selection, talent, and experimental pipelines to realize sustained competitive advantage.

How rapid algorithmic advances, richer biological data, and scalable compute infrastructures are jointly transforming peptide discovery workflows and translational expectations

The landscape of peptide drug discovery is undergoing transformative shifts driven by three intertwined forces: algorithmic sophistication, data availability, and operational scalability. Deep learning architectures have evolved to model sequence-structure-function relationships with increasing fidelity, while graph-based methods and recurrent models enable nuanced representations of peptide interactions and conformational dynamics. Concurrently, the proliferation of high-quality genomics and proteomics datasets, along with richer assay readouts, has enhanced model training and validation, enabling computational hypotheses to be more reliably translated into experimental testing.

Operationally, cloud and hybrid deployment models now allow organizations to scale compute-intensive tasks such as molecular dynamics and generative modeling without prohibitive capital expenditure, while on-premise high-performance computing remains critical for institutions with strict data governance requirements. These technological shifts have catalyzed new collaborative structures: cross-disciplinary teams that couple computational scientists, medicinal chemists, and translational biologists are becoming standard operating practice rather than experimental exceptions. As a result, discovery timelines are compressing and the barrier to iterative design cycles is falling.

Moreover, regulatory and reimbursement environments are starting to recognize the role of in silico evidence in de-risking early development, and payers are paying attention to modality-specific value propositions. Together, these transformative shifts are not only altering how candidates are discovered but also redefining expectations for speed, reproducibility, and transparency in preclinical decision-making.

Evaluating the multifaceted effects of 2025 United States tariffs on peptide discovery supply chains, compute strategies, and experimental prioritization

The cumulative impact of United States tariffs in 2025 introduces complex headwinds and strategic inflection points for organizations operating across the peptide discovery value chain. Tariffs affecting laboratory reagents, specialized peptide synthesis inputs, and select computational hardware components can increase the landed cost of experimental workflows and infrastructure investments, thereby influencing procurement strategies and project prioritization. In response, some organizations are exploring reshoring of critical synthesis capabilities or forming closer partnerships with regional suppliers to stabilize supply continuity and pricing predictability. These supply-side mitigations, however, often require upfront capital commitments and operational retooling.

On the computational front, tariffs that raise the cost of server-class GPUs and related accelerators will likely accelerate interest in cloud-based consumption models where total cost of ownership can be shifted from capital expenditure to operating expenditure. Conversely, entities with stringent data residency or IP protection needs may double down on localized hardware investments, accepting higher costs to preserve control. Tariffs also precipitate indirect effects: increased import costs for lab consumables may concentrate experimentation on in silico approaches and high-throughput virtual screening to reduce wet-lab iterations, thereby favoring platforms that deliver robust predictive accuracy and integration with automation.

Ultimately, the 2025 tariff landscape is reshaping both sourcing strategies and the relative value of computational versus experimental investments. Organizations that proactively redesign procurement, diversify supplier footprints across regions, and optimize hybrid compute architectures will be better positioned to manage cost pressures while sustaining innovation velocity.

A comprehensive segmentation perspective linking technology architectures, therapeutic focuses, end-user needs, peptide modalities, and workflow stages to strategic platform selection and prioritization

A nuanced segmentation analysis reveals how technology choices, therapeutic focus, end-user profiles, peptide classes, and workflow stages collectively define distinct value pools and capability requirements. From a technology perspective, platforms span cloud-based options-encompassing hybrid cloud, private cloud, and public cloud deployments-deep learning approaches that include convolutional neural networks, graph neural networks, and recurrent neural networks, traditional machine learning paradigms such as reinforcement learning, supervised learning, and unsupervised learning, and on-premise platforms that leverage conventional high-performance computing and dedicated servers. Each technology path carries trade-offs in scalability, data governance, and algorithmic suitability for tasks like sequence optimization or structural prediction.

Therapeutic application segmentation includes cardiovascular projects targeting atherosclerosis and heart failure, infectious disease efforts addressing bacterial and viral targets, metabolic disorder programs focused on diabetes and obesity, neurological pursuits in Alzheimer's and Parkinson's, and oncology workstreams spanning hematological malignancies and solid tumors. These indications vary in target tractability, biomarker availability, and clinical validation pathways, which in turn influence the optimal balance between in silico screening and empirical validation.

End users comprise academic and government research institutes-further differentiated into private and public research entities-contract research organizations divided between large and small CROs, and pharmaceutical and biotechnology companies segmented into biotechnology firms and established pharmaceutical companies. Distinctions across these groups affect procurement cycles, risk tolerances, and internal versus outsourced validation strategies. Regarding peptide class, cyclic peptides with head-to-tail or side chain-to-side chain cyclizations, linear peptides categorized as long or short, and peptidomimetics such as beta peptides and peptoids each present unique design challenges and manufacturing considerations. Finally, workflow-stage segmentation covers target identification via genomics and proteomics, lead generation through high-throughput and in silico screening, preclinical validation in vitro and in vivo, and clinical development across Phase I, Phase II, and Phase III. Understanding how these segments interrelate enables organizations to align platform capabilities with therapeutic objectives and operational constraints more precisely.

How Americas, Europe Middle East & Africa, and Asia-Pacific regional dynamics shape platform adoption, regulatory strategy, and supply chain localization for peptide discovery initiatives

Regional dynamics materially influence investment decisions, regulatory navigation, and supply chain design for organizations engaged in AI-driven peptide discovery. In the Americas, a robust innovation ecosystem, well-established venture funding channels, and a dense concentration of biotechnology and pharmaceutical companies foster rapid adoption of computational platforms and close integration between industry and academic labs. Regulatory clarity and sophisticated payer systems in many jurisdictions incentivize translational programs that demonstrate clear clinical value and reproducibility, while domestic manufacturing capacity supports clinical supply for early-stage candidates.

Across Europe, the Middle East & Africa, regulatory fragmentation and diverse reimbursement frameworks necessitate adaptive strategies that emphasize interoperability, data protection compliance, and localized partnerships. Europe's strong academic networks and specialized contract research organizations provide deep domain expertise, but cross-border data transfer rules and regional procurement policies can complicate centralized platform deployment. Investment in hybrid cloud architectures and regional data centers helps mitigate these constraints.

In the Asia-Pacific region, a combination of rapid manufacturing expansion, growing clinical trial capacity, and large patient populations offers significant opportunities for accelerated development and regional commercialization. Governments in several countries are actively supporting biotech innovation through incentives and funding, which can lower barriers to scaling peptide manufacturing and clinical studies. However, heterogeneity in regulatory standards and IP enforcement requires careful market-entry planning and often favors strategic collaborations with local partners to expedite regulatory approvals and supply chain localization. Taking a regionally informed approach to platform deployment, supplier selection, and partnership models is essential to unlocking value across these diverse markets.

Critical competitive and partnership dynamics observed among firms combining peptide chemistry expertise with advanced AI capabilities to accelerate translational pipelines

Key company-level insights reveal recurring strategic patterns among organizations that are leading the integration of AI into peptide drug discovery. Successful companies typically combine domain expertise in peptide chemistry with advanced computational capabilities, creating feedback loops that accelerate model refinement and experimental validation. They invest in cross-functional teams that bridge data science, structural biology, medicinal chemistry, and translational science, ensuring that in silico predictions are rapidly assessed and iteratively improved using empirical data.

Partnership models also stand out: collaborations between platform developers and contract research organizations or academic laboratories enable access to specialized assays and patient-derived datasets, while strategic alliances with manufacturing partners secure scalability for promising candidates. From a product strategy perspective, firms that offer modular platforms-enabling customers to adopt cloud, hybrid, or on-premise configurations-tend to capture a broader set of enterprise clients because they address varied data governance and cost preferences.

Operationally, investment in robust validation frameworks and transparent model explainability increases buyer confidence, particularly when platforms are used to prioritize or de-risk preclinical programs. Firms that couple technical roadmaps with clear regulatory engagement strategies and evidence-generation plans position themselves favorably for enterprise adoption. Finally, organizations that maintain flexible commercial models, including licensing, outcome-linked arrangements, and collaborative research agreements, demonstrate greater resilience in addressing diverse customer procurement cycles and risk appetites.

High-impact actions industry leaders can implement now to align platform choices, governance, and partnerships for rapid and de-risked peptide therapeutic development

Industry leaders should adopt a set of focused, actionable strategies to translate analytic advantages into sustained therapeutic and commercial outcomes. First, align platform selection with organizational risk posture by evaluating whether cloud scaling, hybrid deployments, or on-premise investments best match data sensitivity, regulatory constraints, and total cost objectives. Next, prioritize the formation of integrated teams that pair computational modelers with bench scientists and clinicians to ensure rapid feedback and continuous model validation; institutionalize iterative cycles where experimental results are used to retrain and refine algorithms.

Additionally, diversify supply chains and consider regional manufacturing or supplier partnerships to mitigate tariff and logistical risks, while preserving flexibility through hybrid compute strategies that leverage cloud bursting for peak workloads. Invest in model transparency and standardized validation protocols to build credibility with regulators and collaborators; provide reproducible evidence packages that demonstrate predictive performance across relevant peptide classes and therapeutic contexts. Pursue strategic alliances that grant access to high-quality datasets and specialized assays, and design commercial terms that balance upfront fees with milestone or outcome-based payments to align incentives with customers.

Finally, cultivate a governance framework for data stewardship that addresses privacy, provenance, and reuse. By implementing these measures, organizations can reduce translational friction, accelerate candidate progression, and position themselves to capture downstream value as peptide therapeutics mature toward clinical and commercial milestones.

A rigorous mixed-methods research approach combining primary interviews, technical review, and multi-source triangulation to validate platform claims and strategic implications

This research synthesizes primary and secondary methods to produce an evidence-driven view of the AI-driven peptide discovery landscape. Primary research included structured interviews with leaders across pharmaceutical and biotechnology companies, contract research organizations, academic laboratories, and technology providers, complemented by technical reviews of platform architectures and validation studies. Secondary research drew on peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public disclosures to contextualize development pathways and therapeutic priorities. These inputs were triangulated to ensure robustness and to surface areas of consensus and divergence across stakeholders.

Analytical techniques included qualitative thematic analysis to identify common challenges and strategic responses, as well as comparative assessments of technology approaches across workflow stages. Validation steps involved cross-referencing interview insights with documented case examples and assessing model performance claims against available benchmarking studies. Regional and tariff-related analyses incorporated trade policy documentation and supply chain mapping to evaluate potential operational impacts. Throughout, the methodology emphasized transparency in assumptions, reproducibility in data synthesis, and the use of multiple evidence streams to mitigate single-source bias.

The result is a structured framework that links technological capabilities to therapeutic application needs and operational constraints, supporting practical recommendations for platform selection, partnership models, and implementation sequencing.

Concluding insights on integrating AI platforms with operational rigor and strategic partnerships to translate computational peptide discovery into clinically relevant therapeutics

In conclusion, AI-driven peptide discovery is transitioning from experimental innovation to an operational cornerstone for organizations intent on accelerating therapeutic pipelines. Technological advances in deep learning and graph-based modeling, paired with scalable compute options and richer biological datasets, are enabling more reliable in silico hypothesis generation and prioritization. These capabilities are most effective when embedded within cross-functional teams and supported by governance practices that ensure reproducibility and regulatory traceability.

The 2025 tariff environment and regional heterogeneity in regulation and manufacturing capacity introduce pragmatic constraints that require adaptive procurement and partnership strategies. By aligning technology choices-whether cloud, hybrid, or on-premise-with data governance requirements, and by investing in supplier diversification and regional partnerships, organizations can maintain innovation velocity while managing cost and compliance risks. Firms that combine technical rigor with clear validation evidence, flexible commercial terms, and strategic collaborations will be best positioned to convert computational predictions into clinically meaningful peptide therapeutics.

Ultimately, success will favor organizations that treat AI platforms not as isolated tools but as integral elements of an end-to-end discovery-to-clinic strategy, continuously integrating empirical learning and market feedback to refine both models and operational approaches.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. AI-driven Peptide Drug Discovery Platform Market, by Technology Type

  • 8.1. Cloud Based Platform
    • 8.1.1. Hybrid Cloud
    • 8.1.2. Private Cloud
    • 8.1.3. Public Cloud
  • 8.2. Deep Learning Platform
    • 8.2.1. Convolutional Neural Network
    • 8.2.2. Graph Neural Network
    • 8.2.3. Recurrent Neural Network
  • 8.3. Machine Learning Platform
    • 8.3.1. Reinforcement Learning
    • 8.3.2. Supervised Learning
    • 8.3.3. Unsupervised Learning
  • 8.4. On Premise Platform
    • 8.4.1. Conventional Hpc
    • 8.4.2. Dedicated Servers

9. AI-driven Peptide Drug Discovery Platform Market, by Therapeutic Application

  • 9.1. Cardiovascular
    • 9.1.1. Atherosclerosis
    • 9.1.2. Heart Failure
  • 9.2. Infectious Diseases
    • 9.2.1. Bacterial
    • 9.2.2. Viral
  • 9.3. Metabolic Disorders
    • 9.3.1. Diabetes
    • 9.3.2. Obesity
  • 9.4. Neurological
    • 9.4.1. Alzheimers
    • 9.4.2. Parkinsons
  • 9.5. Oncology
    • 9.5.1. Hematological Malignancies
    • 9.5.2. Solid Tumors

10. AI-driven Peptide Drug Discovery Platform Market, by Peptide Class

  • 10.1. Cyclic Peptides
    • 10.1.1. Head To Tail
    • 10.1.2. Side Chain To Side Chain
  • 10.2. Linear Peptides
    • 10.2.1. Long Peptides
    • 10.2.2. Short Peptides
  • 10.3. Peptidomimetics
    • 10.3.1. Beta Peptides
    • 10.3.2. Peptoids

11. AI-driven Peptide Drug Discovery Platform Market, by End User

  • 11.1. Academic & Government Research Institutes
    • 11.1.1. Private Research Institutes
    • 11.1.2. Public Research Institutes
  • 11.2. Contract Research Organizations
    • 11.2.1. Large Cro Organizations
    • 11.2.2. Small Cro Organizations
  • 11.3. Pharmaceutical & Biotechnology Companies
    • 11.3.1. Biotechnology Companies
    • 11.3.2. Pharmaceutical Companies

12. AI-driven Peptide Drug Discovery Platform Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. AI-driven Peptide Drug Discovery Platform Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. AI-driven Peptide Drug Discovery Platform Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States AI-driven Peptide Drug Discovery Platform Market

16. China AI-driven Peptide Drug Discovery Platform Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Atombeat, Inc.
  • 17.6. Aurigene Discovery Technologies Limited
  • 17.7. Cradle, Inc.
  • 17.8. Creative Peptides, Inc.
  • 17.9. Deep Genomics Inc.
  • 17.10. DenovAI Biotech, Inc.
  • 17.11. Fujitsu Limited
  • 17.12. Generate Biomedicines, Inc.
  • 17.13. Gubra ApS
  • 17.14. Iktos SA
  • 17.15. Insilico Medicine, Inc.
  • 17.16. Koliber Biosciences, Inc.
  • 17.17. Numerion Labs, Inc.
  • 17.18. Nuritas Limited
  • 17.19. Pepticom, Inc.
  • 17.20. Peptilogics, Inc.
  • 17.21. Relay Therapeutics, Inc.
  • 17.22. Space Peptides, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDE CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CLOUD BASED PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CLOUD BASED PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CLOUD BASED PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CLOUD BASED PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HYBRID CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HYBRID CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HYBRID CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PRIVATE CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PRIVATE CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PRIVATE CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PUBLIC CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PUBLIC CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEEP LEARNING PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEEP LEARNING PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEEP LEARNING PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEEP LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY GRAPH NEURAL NETWORK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY GRAPH NEURAL NETWORK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY GRAPH NEURAL NETWORK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY RECURRENT NEURAL NETWORK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY RECURRENT NEURAL NETWORK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY RECURRENT NEURAL NETWORK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY MACHINE LEARNING PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY MACHINE LEARNING PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY MACHINE LEARNING PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY MACHINE LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY REINFORCEMENT LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY REINFORCEMENT LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY REINFORCEMENT LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SUPERVISED LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SUPERVISED LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SUPERVISED LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY UNSUPERVISED LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY UNSUPERVISED LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY UNSUPERVISED LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ON PREMISE PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ON PREMISE PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ON PREMISE PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ON PREMISE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONVENTIONAL HPC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONVENTIONAL HPC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONVENTIONAL HPC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEDICATED SERVERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEDICATED SERVERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEDICATED SERVERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ATHEROSCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ATHEROSCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY OBESITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY OBESITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY OBESITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY NEUROLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY NEUROLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY NEUROLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY NEUROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ALZHEIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ALZHEIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ALZHEIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PARKINSONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PARKINSONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PARKINSONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDE CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CYCLIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CYCLIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CYCLIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HEAD TO TAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HEAD TO TAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HEAD TO TAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SIDE CHAIN TO SIDE CHAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SIDE CHAIN TO SIDE CHAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SIDE CHAIN TO SIDE CHAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LINEAR PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LINEAR PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LINEAR PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LINEAR PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LONG PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LONG PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LONG PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SHORT PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SHORT PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SHORT PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDOMIMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDOMIMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDOMIMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDOMIMETICS, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY BETA PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY BETA PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY BETA PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PRIVATE RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PRIVATE RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PRIVATE RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LARGE CRO ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LARGE CRO ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LARGE CRO ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SMALL CRO ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SMALL CRO ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SMALL CRO ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CLOUD BASED PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEEP LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY MACHINE LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ON PREMISE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY NEUROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDE CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LINEAR PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDOMIMETICS, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CLOUD BASED PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEEP LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY MACHINE LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ON PREMISE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY NEUROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDE CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LINEAR PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDOMIMETICS, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CLOUD BASED PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEEP LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY MACHINE LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ON PREMISE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY NEUROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDE CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LINEAR PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDOMIMETICS, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CLOUD BASED PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEEP LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY MACHINE LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ON PREMISE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY NEUROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDE CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LINEAR PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDOMIMETICS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CLOUD BASED PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEEP LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY MACHINE LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ON PREMISE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY INFECTI